Sandostatin Injection is available as: sterile 1-mL ampuls in 3 strengths, containing 50, mcg octreotide (as acetate), and sterile 5-mL multi-dose vials in 2. Sep 3, Octreotide Acetate (Sandostatin ®) – Intravenous (IV) Dilution. Octreotide (Sandostatin) is the longer acting synthetic analogue of the naturally In patients with cancer and inoperable bowel obstruction octreotide rapidly.
|Published (Last):||21 February 2006|
|PDF File Size:||12.37 Mb|
|ePub File Size:||5.34 Mb|
|Price:||Free* [*Free Regsitration Required]|
All the information available at present indicates that the findings in rats are specific and have no significance for the use of the drug in humans see section 5. Sandostatin is to be used in association with specific treatment such as endoscopic sclerotherapy.
Bradycardia is a common adverse reaction with somatostatin analogues. Show table of contents Hide table of contents 1. In patients with insulinomas, octreotide because of its greater relative potency in inhibiting the secretion of GH and glucagon than that of insulin, and because of the shorter duration of its inhibitory action on insulin, may increase the depth and prolong the duration of hypoglycaemia.
Pain with subcutaneous administration may be reduced by using the smallest volume that will deliver the desired dose. Subcutaneous administration Patients who are to self-administer the drug by s. Method of administration Sandostatin may be administered directly by subcutaneous s.
Investigations Increased alkaline phosphatase levels, increased gamma glutamyl transferase levels. Depressed vitamin B12 levels and abnormal Schilling’s tests have been observed in some patients receiving octreotide therapy.
In emergency situations may be given by IV bolus undiluted over 3 to 5 minutes. Find out vosis here. Sandostatin can help to further reduce gastric acid hypersecretion and improve symptoms, including diarrhoea, as it provides suppression of elevated gastrin levels, in some patients.
Dosing & Administration
Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis. Therapy with proton pump inhibitors doosis H2 receptor blocking agents generally controls gastric acid hypersecretion. Dose adjustment of medicinal products such as beta blockers, calcium channel blockers, or agents to control fluid and electrolyte balance may be necessary when Sandostatin is administered concomitantly see section 4.
Any unused solution or waste material should be disposed of ocreotide accordance with local requirements.
Ultrasonic examination of the gallbladder before, and at about 6- to month intervals during Octreotide therapy is therefore recommended.
GH in patients with acromegaly. Repeat moderate shaking for another 30 seconds if the powder is not completely suspended. If evidence of tumour expansion appears, alternative procedures may be advisable. The dose can be adjusted according to the responses of TSH and thyroid hormones. Octreotide produces improvement of diarrhoea, octreotdie hence weight gain, in those patients affected.
At least 5 days of treatment will be needed to judge the efficacy. In rare instances, gastrointestinal side effects may resemble acute intestinal obstruction, with progressive abdominal distension, severe epigastric pain, otreotide tenderness and guarding. Sandostatin is not compatible in Total Parenteral Nutrition TPN solutions because of the formation of a glycosyl octreotide conjugate which may decrease the efficacy of the product.
From a microbiological point of view, the diluted solution should preferably be used immediately. General disorders and administration site conditions.
Local site reactions In a week toxicity study in rats, predominantly in males, sarcomas were noted at the s.
Sandostatin 50 microgram/1 ml, solution for injection/infusion
The treatment effects of octreotide were rosis observed in 21 patients and pooled with series of 37 published cases. Use in the elderly There is no evidence of reduced tolerability or altered dosage requirements in elderly patients treated with Sandostatin.
Gallbladder abnormalities may occur: There is no evidence of reduced tolerability or altered dosage requirements in elderly patients treated with Sandostatin. H01CB02 Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action.
Common cases of bradycardia have been reported. It may be diluted in volumes of 50 — mL and infused intravenously over minutes or administered by IV push over 3 minutes.
If no relevant octrreotide in GH levels and no improvement in clinical symptoms have been achieved within 3 months of starting treatment with Sandostatin, therapy should be discontinued. Dehydration General disorders and administration site conditions Very common: Store in the original package in order to protect from light.
Emergency management to stop bleeding and to protect from re-bleeding owing to gastro-oesophageal varices in patients with cirrhosis.
Dilution Octreotide -Sandostatin ® – GlobalRPH
Long-term treatment of the profuse watery diarrhea octreoyide with VIP-secreting tumors. For patients on a stable dose of Octreotide assessment of GH should be made every 6 months. Octreotide may affect glucose regulation.